-
Avrobio Inc. NASDAQ:AVRO AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Its ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by its industry leading plato® gene therapy platform, its foundation designed to deliver gene therapy worldwide. The company is headquartered in Cambridge, Mass., with an office in Toronto, Ontario.
Location: | Website: www.avrobio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.59%
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AVR-RD-05 Details Mucopolysaccharidoses, Mucopolysaccharidosis type II, Rare diseases, Rare genetic disease, Genetic disorder | Failed Discontinued | |
AVR-RD-04 Details Cystinosis | Failed Discontinued | |
AVR-RD-02 Details Gaucher disease | Failed Discontinued | |
AVR-RD-01 Details Genetic disorder, Fabry disease | Failed Discontinued |